AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary artery disease (CAD).

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European ...

According to US secondary stroke prevention guidelines, patients with ESUS should not be treated with anticoagulants or ...

Cobblestone Capital Advisors LLC NY raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 4.6% during the second quarter, according to the company in its most recent ...

Submaximal balloon angioplasty for symptomatic intracranial atherosclerotic stenosis (ICAS) improved outcomes over aggressive ...

At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...

AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (ADC) technology, publishing phase 1 data on candidates that could compete with molecules from ...

British pharma giant AstraZeneca plans to spend $135 million to expand the manufacturing operations footprint of its site in Södertälje, Sweden, by 50%. The project calls for a 2,700-square ...